The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy

Heart Fail Clin. 2022 Jan;18(1):1-8. doi: 10.1016/j.hfc.2021.07.013. Epub 2021 Oct 22.

Abstract

Genetic testing in children with hypertrophic cardiomyopathy (HCM) can modify clinical management and lifestyle counseling. However, predicting long-term outcome and response to management in individual patients remains challenging, because of the peculiar genetic heterogeneity of the disease in the pediatric age range. Children with HCM secondary to an inborn error of metabolism or malformation syndromes tend to have a worse outcome compared with those with the classic sarcomeric form. Among the latter, adverse genetic features are represented by the identification of a pathogenic variant in MYH7, often associated with severe hypertrophy, a complex genotype, or a de novo variant.

Keywords: Cardiomyopathies in children; Genetic analysis; Genotype; Phenotype; Prognosis.

Publication types

  • Review

MeSH terms

  • Cardiac Myosins* / genetics
  • Cardiomyopathy, Hypertrophic* / genetics
  • Child
  • Genotype
  • Humans
  • Myosin Heavy Chains / genetics
  • Phenotype

Substances

  • Cardiac Myosins
  • Myosin Heavy Chains